Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
Conditions: Gastric Neoplasms
Age: Between 18 - 100 Years
Gender: Male or Female
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required